MUMBAI, India, July 24 -- Intellectual Property India has published a patent application (202611065149 A) filed by Banasthali Vidyapith; Dr. Sonia Zeba Hashmi; and Prof. Jaya Dwivedi on May 23, 2026, for S-Triazine-Based Molecular Hybrids As Potent Inhibitors Of Hpv E6 And E7 Oncoproteins For The Treatment Of Cervical Cancer.
Inventors include Ms. Diksha Bareth; Dr. Sonia Zeba Hashmi; Ms. Divya Kumari; Ms. Anshita Paliwal; Dr. Pracheta Janmeda; Prof. Jaya Dwivedi; and Prof. Swapnil Sharma.
The application for the patent was published on July 17, 2026, under issue no. 29/2026.
Abstract: The present invention relates to a novel molecular hybrid compound of Formula III, based on an s-triazine core, characterized by its ability to inhibit HPV E6 and E7 oncoproteins for use in the treatment of cervical cancer. The compound comprises an electron- deficient s-triazine core; a cyclopropylamine moiety, which is further linked to mesitylene through -NH- and/or -O- spacer, which is again connected to a heterocyclic ring (5-phenylisoxazole/ 4-phenylpyrimidine-2-thiol/ 4-phenylpyrimidin-2-ol/ 5-phenyl-1H- pyrazole) via phenylamino or phenoxide spacers to enhance anticancer activity, preferably against HPV E6 and E7 oncoproteins for the treatment of cervical cancer. ……….. Formula III wherein R and X are spacer groups selec-NHted-, - Ofr-o gmro up, and Z is selected from the group consisting of substituted heterocyclic rings comprising isoxazole, pyrimidine, and pyrazole.
Disclaimer: Curated by HT Syndication.
